Health Care • Medical/Dental Instruments
$29.69 ▼ -0.92
(-3.01%)
MKT CAP: $1.82B • VOL: 324.9K
52W L $17 52W H $31
KMTS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-04-30 | FY 2024
FILED 2025-04-30 | FY 2023
FILED 2024-04-30 |
|---|---|---|---|
| Revenue (Total Sales) | $95.1M | $59.8M | $27.8M |
| YoY Revenue Growth % | +59.0% | +115.1% | — |
| Gross Profit | $48.9M | $24.2M | — |
| Gross Margin % | 51.4% | 40.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$134.7M | -$106.4M | -$85.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$131.6M | -$113.8M | -$94.1M |
| EBITDA (Normalized) | -$106.8M | -$88.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$81.7M | -$77.6M | -$72.2M |
| Capital Expenditures (CapEx) | $34.9M | $22.9M | — |
| Free Cash Flow (FCF) | -$116.6M | -$100.5M | -$72.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | — | — |
| Cash & Short-Term Equivalents | $291.3M | $54.4M | — |
| Total Debt (Short + Long Term) | $42.3M | — | — |
| Total Stockholders' Equity | $288.0M | — | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KMTS.